Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Hemera Biosciences LLC logo — Developing HMR59, an intravitreal gene therapy, to preserve...

Hemera Biosciences LLC

Developing HMR59, an intravitreal gene therapy, to preserve vision in eyes with dry age-related macular degeneration.

Founded 2010 United States Waltham, United States 1 employees Venture round Total: $1.30M Biotechnology

General Information

Company Name Hemera Biosciences LLC
Founded Year 2010
Location United States Waltham, United States
Employees 1
Industries Biotechnology
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Hemera Biosciences LLC. To contact Hemera Biosciences LLC, visit hemerabiosciences.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Hemera Biosciences LLC compare?

A PDF of Hemera Biosciences LLC and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Hemera Biosciences LLC soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Hemera Biosciences LLC

Hemera Biosciences LLC is a biotechnology startup based in the United States, founded in 2010. The company is focused on developing HMR59, an intravitreal gene therapy, to preserve vision in eyes with dry age-related macular degeneration (AMD). Their slogan succinctly captures their mission: "Developing HMR59, an intravitreal gene therapy, to preserve vision in eyes with dry age-related macular degeneration." As a clinical stage gene therapy company, Hemera is driven by the frustration experienced by physicians and scientists in their inability to provide treatment for patients with macular degeneration. Their solution is the gene therapy HMR59, which is currently undergoing FDA clinical trial testing as a one-time treatment for both the dry and wet forms of AMD. Notably, the therapy is administered during a routine office visit with the goal of preserving vision that will endure the life of the patients. The company's last recorded investment was a $1.30M Venture Round investment on 01 April 2013. The investors associated with this round are not specified in the available information. As venture capital analysts, it's important to consider the potential of Hemera Biosciences LLC in addressing a significant unmet medical need and the progress of their clinical trials in evaluating the attractiveness of their investment opportunity.

Business keywords: gene therapy, clinical stage, AMD treatment, injection therapy, FDA clinical trial, macular degeneration, age-related diseases, vision preservation, complement gene therapy, ophthalmology, clinical research, biopharmaceuticals, recombinant molecules, eye diseases

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $1.30M -
01 Apr 2013

Hemera Biosciences LLC Alternatives & Competitors

View All Alternatives
Hemera Biosciences LLC vs
Adverum Biotechnologies
Adverum Biotechnologies United States

We are on a global mission to establish gene therapy as a new standard of care for the leading cause...

Acquired
133 employees
Biotechnology, Health and Wellness
Hemera Biosciences LLC vs
EyeBio
EyeBio United Kingdom

Developing a new generation of therapies to protect, restore, and improve vision

Acquired
109 employees
Biotechnology
Hemera Biosciences LLC vs
Alkeus Pharmaceuticals, Inc.
Alkeus Pharmaceuticals, Inc.

Transformation in Sight

Series B
58 employees
Biotechnology, Medical Devices
Also compare with: Hemera Biosciences LLC vs 4D Molecular Therapeutics 4D Molecular Therapeutics Hemera Biosciences LLC vs Lysoclear Lysoclear View all alternatives

FAQ About Hemera Biosciences LLC

Developing HMR59, an intravitreal gene therapy, to preserve vision in eyes with dry age-related macular degeneration.
Hemera Biosciences LLC was founded in 2010.
Hemera Biosciences LLC is headquartered in Waltham, United States.
Hemera Biosciences LLC operates in Biotechnology. Its work centres on gene therapy, clinical stage, AMD treatment and injection therapy.
Hemera Biosciences LLC has approximately 1 employees.
Hemera Biosciences LLC has completed 1 funding round, raising a total of $1.30M. The latest funding stage is Venture round.
Top alternatives and competitors to Hemera Biosciences LLC include Adverum Biotechnologies, EyeBio, Alkeus Pharmaceuticals, Inc., Complement Therapeutics, Beacon Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Hemera Biosciences LLC and Adverum Biotechnologies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Hemera Biosciences LLC, https://bouncewatch.com/company/hemera-biosciences-llc, updated 11 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout